Documents & Resources

IIVS Posters – SOT 2023 Annual Meeting

March 31, 2023

IIVS presented several posters at SOT 2023. This post includes links to the full PDF versions of each poster presented. (more…)

Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

February 23, 2023

The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific and technical approaches for conducting in vitro assays, to assess potential toxicity within and across tobacco and various next generation nicotine and tobacco products (NGPs), including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS). (more…)

Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 2

February 16, 2023

This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan...

Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1

February 7, 2023

This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan...

Good In Vitro Method Practices Certification: A Roadmap for Implementation and Harmonization

October 7, 2022
The Organization for Economic Cooperation and Development (OECD) guidance document on Good In Vitro Method Practices (GIVIMP) details a set of quality standards to improve both the quality of and confidence in newly developed, and routinely executed in vitro methods. Currently a practical guide to implement GIVMP standards is missing; leaving organizations to define the best approach for themselves.

IIVS is Pleased to Announce the Co-Publication of Three Articles

August 25, 2022

IIVS is pleased to announce the co-publication of several respiratory-based articles highlighting: the characterization and recommendations for non-animal techniques used to model mucociliary clearance in human-derived test systems, the dosimetry of tobacco products for in vitro testing and a third article covering the use of New Approach Methodologies to nicotine containing products in a regulatory environment.

Key Challenges for In Vitro Testing of Tobacco Products for Regulatory applications: Recommendations for Dosimetry

Ciliary Beat Frequency: Proceedings and Recommendations from a Multi-laboratory Ring Trial Using 3-D Reconstituted Human Airway Epithelium to Model Mucociliary Clearance

Use of New Approach Methodologies (NAMs) to Meet Regulatory Requirements for the Assessment of Tobacco and Other Nicotine-Containing Products

Eye Irritation Testing and Beyond

May 18, 2022

If you missed the webinar: Establishing Scientific Confidence in New Approach Methodologies (NAMs): Eye Irritation Testing and Beyond, co-sponsored by the Risk Assessment and In Vitro and Alternative Methods Specialty Sections of SOT, a recording is now posted. Speakers included Hans Raabe (IIVS) and Dr. Amy Clippinger...

IIVS Posters at SOT 2022

April 14, 2022

Thank you to all who visited our booth or poster sessions at the 2022 Society of Toxicology annual meeting. If you would like copies of any of the poster presented we now have them available to view online (more…)

Evaluating the Use of Predictive Models in Combination with In Vitro Assays

April 11, 2022

IIVS is excited to announce the publication of 2 papers evaluating the use of predictive models in combination with in vitro assays to provide a quantitative assessment of skin sensitization potential. This work is presented Drs. Frank Gerberick (GF3 Consultancy, Chief Scientific Advisor to IIVS) and Andreas Natsch (Senior Research Fellow at Givaudan ) (more…)